They are the same drug. Both are semaglutide, a GLP-1 analogue that the Wegovy label describes as having "94% sequence homology to human GLP-1".5 Both are made by Novo Nordisk, both come in a weekly pen, and at the same dose they do the same thing to the same receptors. Anyone who tells you one "works differently" is selling something.
What differs is the box, and the box turns out to decide almost everything practical: what a doctor can prescribe it for, what a plan will pay, how high the dose can go, and what it costs in cash. So the honest version of this comparison is short on pharmacology and long on paperwork.
What each box says it is for
Ozempic came first, in 2017, as a diabetes drug. Its approved uses are all for people with type 2 diabetes: to improve blood sugar, to cut the risk of heart attack and stroke in those with known heart disease, and to slow kidney disease.1 Weight loss is a side effect the label acknowledges and the world noticed. It is not something Ozempic is approved to be prescribed for.
Wegovy is the same molecule submitted again, in 2021, at a higher dose, for a different purpose: to reduce and maintain body weight in adults with obesity or overweight, and since 2024 also to cut cardiovascular risk in people with established heart disease and obesity.2 It is the one a plan can cover for weight, and the one a doctor can write for weight without going off-label.
The reason this matters more than it sounds: US insurers cover by indication, not by molecule. A plan that refuses "weight-loss drugs" will refuse Ozempic prescribed for weight even though it is chemically identical to a Wegovy it might cover. The box is the policy.
The dose ceilings
Both climb the same ladder from 0.25 mg, but they stop at different rungs.
| Ozempic | Wegovy | |
|---|---|---|
| Starting dose | 0.25 mg | 0.25 mg |
| Standard maintenance | 0.5, 1 mg | 1.7, 2.4 mg |
| Maximum | 2 mg | 2.4 mg, or 7.2 mg HD pen |
| Tablet | No (Rybelsus is the diabetes tablet) | Yes: 1.5, 4, 9, 25 mg |
The weight-loss trials that made semaglutide famous were run at 2.4 mg. Ozempic's ceiling is below that. So a person taking Ozempic for weight is, by the label, capped at a dose the weight-loss evidence was not generated at. In practice the two drugs overlap heavily through 1 mg, and the difference shows at the top of the ladder, which is where people who stall want to go. The dose ladder guide walks each step.
Wegovy also now has two things Ozempic does not: a 7.2 mg high-dose pen above the standard ladder, and a daily tablet, which Novo calls "the only semaglutide tablet that's FDA-approved for weight loss in adults".4 Ozempic's tablet cousin is Rybelsus, and that is a diabetes product.
What each costs, in cash
Novo sells both direct to cash patients through its own pharmacy, and it publishes the prices.3
| Direct from Novo, per month | Ozempic | Wegovy |
|---|---|---|
| Pen, 0.25 to 1 mg | $349 | $349 |
| Pen, 1.7 and 2.4 mg | not available | $349 |
| Pen, 2 mg | $499 | n/a (Wegovy uses 1.7 / 2.4) |
| HD pen, 7.2 mg | none | $399 |
| Tablet | none | $149 (1.5 mg), $199 (4 mg), $299 (9, 25 mg) |
| New-patient intro | $199 for two fills at 0.25 / 0.5 mg, to 31 Dec 2026 | same |
The counter-intuitive one: Ozempic is more expensive than Wegovy at the top of its own ladder. Its 2 mg pen is $499 while Wegovy's 2.4 mg pen is $349. The diabetes product costs $150 a month more than the weight product for a smaller dose. If you are paying cash for semaglutide and weight is the goal, there is no price argument for Ozempic at all, and the Wegovy tablet at $149 undercuts both pens.
What each costs through a plan
Here the box does its real work. For type 2 diabetes, Ozempic is one of the most widely covered drugs in the country, and the maker's card can bring it to $25 for commercially insured patients. For weight loss, the same pen is routinely denied, because the plan's formulary lists it under diabetes and the prescription does not match.
Wegovy is the drug a plan can cover for weight. Whether it does is plan-specific, and here is what eight insurers' own documents say:
Which one fits you
The lowest price, full stop
cheapest all-in program we track at $69/mo
chosen from 35 qualifying programs · full breakdown · is it legit?
Tirzepatide specifically
cheapest verified tirzepatide at $69/mo
chosen from 34 qualifying programs · full breakdown · is it legit?
A pill, not an injection
cheapest oral option at $99/mo
chosen from 10 qualifying programs · full breakdown · is it legit?
FDA-approved brand medication
cheapest program dispensing branded drugs at $69/mo, which is the only route that is FDA-approved
chosen from 15 qualifying programs · full breakdown · is it legit?
Your plan billed for you
cheapest program that will bill your insurance, from $99/mo
chosen from 5 qualifying programs · full breakdown · is it legit?
No membership fee at all
$69/mo with nothing added on top
chosen from 30 qualifying programs · full breakdown · is it legit?
The strongest review record
4.9 out of 5 across 39,297 published reviews, at $208/mo
chosen from 15 qualifying programs · full breakdown · is it legit?
Every row is computed from today’s verified prices. Nobody picks the winners, and no program can pay to appear here.
The pattern is consistent: Ozempic for weight loss is "no" almost everywhere, Wegovy is "depends on your plan" almost everywhere, and the exceptions are TRICARE (covers Wegovy) and Humana (covers neither). Each linked sheet quotes the insurer verbatim. If you have diabetes and want Ozempic, you are in the easy case. If you want semaglutide for weight, the coverage guide is about Wegovy, and the appeal guide is for when it is refused.
The third box: compounded semaglutide
Because both brands are one molecule, the cheap route is also one molecule. Licensed compounding pharmacies sell semaglutide through telehealth programs at a fraction of Novo's price. Same active ingredient, no FDA approval of the finished product, and the pharmacy's licensing is what stands behind it. Novo's own line is blunt: "Only Novo Nordisk manufactures FDA-approved semaglutide medicines".1 Both things are true at once. Here is what the compounded route costs today, from every seller we track, verified on their own pages:
From $69 a month against $349 for either brand's pen. For a lot of people paying cash that gap, roughly $3,400 a year, is the whole decision, and it is why "Wegovy vs Ozempic" is often the wrong question: the real comparison is branded semaglutide versus compounded, and how to check the seller before you decide.
So which one
- Type 2 diabetes, insured: Ozempic. It is approved for you, widely covered, and the card takes it to $25.
- Weight loss, insured: Wegovy. It is the box a plan can cover for weight; Ozempic on a weight prescription will usually be refused.
- Weight loss, paying cash: not Ozempic. Wegovy's pen is the same price to 1 mg and cheaper above it, and the Wegovy tablet is cheaper than either pen. Below all of them is compounded semaglutide, with the trade-off stated above.
- Want the higher doses: Wegovy. 2.4 mg and 7.2 mg exist only on that box.
- Want a pill: Wegovy, or Rybelsus if the reason is diabetes.
The honest summary
There is no clinical contest between Wegovy and Ozempic because there is no clinical difference at the doses they share. The contest is administrative: Ozempic is the diabetes box and Wegovy is the weight box, and the box decides your coverage, your ceiling and, at the top of the ladder, your cash price. Decide which box matches your prescription, then decide whether the brand is worth $280 a month more than the compounded version of the same molecule.